Aranesp 300 micrograms (EPO) (darbepoetin alfa) is approved by the FDA for the treatment of anemia (a disease that decreases the number of red blood cells) associated with chronic kidney failure or caused by chemotherapy.
Darbepoetin alfa differs from recombinant human erythropoietin (epoetin alfa) mainly by its duration of action. Aranesp 300 micrograms (EPO) maintains blood levels about three times longer, with a much longer therapeutic window. This means that patients will need to use darbepoetin alfa much less often than epoetin alfa. When epoetin alfa is usually used three times a week, darbepoetin is used three times less often.
This significantly increases the comfort of using the drug in patients, especially if the patient undergoes a medical examination during treatment.
Athletes who practice aerobic sports use darbepoetin to produce red blood cells. This is no secret, because in sports where endurance is required, the practice of doping blood has been popular for years. This procedure involves allocating and storing a specified amount of red blood cells from the athlete’s body for further infusion into the blood.
When adding red blood cells to the body before the competition (when the body has already regained lost blood volume), the athlete has an increased concentration of red blood cells in the body.
As a result, blood begins to transport oxygen more efficiently, and athletes experience significantly increases in endurance. Such a procedure can be quite dangerous as proper storage and use of blood is quite a complicated process.
Also for sale at anabolen-online.nl